A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Spinocerebellar Degenerations, brain disorder, central nervous system disorder, cerebellar disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hereditary disease, inherited neurodegenerative disorder, intestinal disorder, neoplasm, nervous system disorder, neurodegenerative disease, rectal disorder, spinal cord disorder	Recruiting	Phase 2	2026-04-07		NCT07506109

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tianjin Medical University Cancer Institute and Hospital	287

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	1
Peking Union Medical College Hospital	Beijing	China	48
Tianjin Medical University Cancer Institute and Hospital	Tianjin	China	20
West China Hospital Sichuan University	Chengdu	China	10